Free Trial

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

+0.06 (+1.82%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.07 million shs
Average Volume
1.15 million shs
Market Capitalization
$632.21 million
P/E Ratio
Dividend Yield
Price Target

Arbutus Biopharma MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
29.4% Upside
$4.33 Price Target
Short Interest
2.83% of Shares Sold Short
Dividend Strength
News Sentiment
0.86mentions of Arbutus Biopharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.39) to ($0.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.13 out of 5 stars

Medical Sector

768th out of 931 stocks

Pharmaceutical Preparations Industry

356th out of 426 stocks

ABUS stock logo

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ABUS Stock Price History

ABUS Stock News Headlines

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 4.7%
Arbutus Biopharma Corp ABUS
Arbutus: Q1 Earnings Snapshot
Arbutus Biopharma earnings: here's what to expect
Arbutus Biopharma Corp
See More Headlines
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$18.14 million
Book Value
$0.63 per share


Free Float
Market Cap
$632.21 million

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Michael J. McElhaugh (Age 49)
    Co-Founder, Interim President, CEO & Director
    Comp: $606.62k
  • Dr. Michael J. Sofia Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $628.43k
  • Mr. David C. Hastings CPA (Age 63)
    CFO & Chief Accounting Officer
    Comp: $647.1k
  • Ms. Lisa M. Caperelli
    Vice President of Investor Relations
  • Mr. J. Christopher Naftzger BA (Age 57)
    Esq., J.D., General Counsel, Chief Compliance Officer & Secretary
  • Ms. Shannon Briscoe SPHR
    Vice President of Human Resources
  • Dr. Karen Sims M.D. (Age 53)
    Ph.D., Chief Medical Officer
  • Mr. R. Hector Mackay-Dunn B.A. (Age 73)
    J.D., L.L.B., Q.C., Corporate Secretary

ABUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings
or view top-rated stocks.

What is Arbutus Biopharma's stock price target for 2024?

3 Wall Street analysts have issued 1 year price objectives for Arbutus Biopharma's shares. Their ABUS share price targets range from $4.00 to $5.00. On average, they anticipate the company's share price to reach $4.33 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price.
View analysts price targets for ABUS
or view top-rated stocks among Wall Street analysts.

How have ABUS shares performed in 2024?

Arbutus Biopharma's stock was trading at $2.50 on January 1st, 2024. Since then, ABUS shares have increased by 34.0% and is now trading at $3.35.
View the best growth stocks for 2024 here

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a drop in short interest in May. As of May 15th, there was short interest totaling 5,340,000 shares, a drop of 8.1% from the April 30th total of 5,810,000 shares. Based on an average daily volume of 1,150,000 shares, the short-interest ratio is currently 4.6 days.
View Arbutus Biopharma's Short Interest

When is Arbutus Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our ABUS earnings forecast

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) released its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). The biopharmaceutical company earned $1.53 million during the quarter, compared to the consensus estimate of $2.16 million. Arbutus Biopharma had a negative net margin of 572.81% and a negative trailing twelve-month return on equity of 62.68%.

What ETFs hold Arbutus Biopharma's stock?

ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Morningstar US Small Growth (MSGR).Amplify Treatments, Testing and Advancements ETF (GERM).

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Whitefort Capital Management LP (6.82%), Kennedy Capital Management LLC (0.23%), BNP Paribas Financial Markets (0.19%), Susquehanna Fundamental Investments LLC (0.05%), Tidal Investments LLC (0.02%) and Verus Capital Partners LLC (0.02%).
View institutional ownership trends

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABUS) was last updated on 5/29/2024 by Staff

From Our Partners